Daniel K Martin1, Ortrud Uckermann1, Aiko Bertram1, Corina Liebner1, Sandy Hendruschk1, Kerim Hakan Sitoci-Ficici1, Gabriele Schackert1, Edith M Lord2, Achim Temme3, Matthias Kirsch4. 1. Department of Neurosurgery, Carl Gustav Carus University Hospital, Dresden University of Technology, Dresden, Germany. 2. Department of Microbiology and Immunology, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, U.S.A. 3. Department of Neurosurgery, Carl Gustav Carus University Hospital, Dresden University of Technology, Dresden, Germany CRTD/DFG-Center for Regenerative Therapies Dresden, Dresden University of Technology, Dresden, Germany. 4. Department of Neurosurgery, Carl Gustav Carus University Hospital, Dresden University of Technology, Dresden, Germany CRTD/DFG-Center for Regenerative Therapies Dresden, Dresden University of Technology, Dresden, Germany matthias.kirsch@uniklinikum-dresden.de.
Abstract
BACKGROUND: The formation of brain metastases is intrinsically linked to concomitant angiogenesis. The purpose of the present study was to investigate the combined effects of interleukin-12 (IL-12) and EMD121974 on the growth and distribution of melanoma brain metastases since both substances may interact with important steps in the cascade of brain metastases formation. MATERIALS AND METHODS: Brain metastases were induced by either stereotactic implantation of cells to the brain parenchyma or by injection of the melanoma cells into the internal carotid artery to mimic hematogenous metastatic spread in mice. Naive or IL-12-overexpressing murine K1735 melanoma cells were used either alone or in combination with intraperitoneal anti-integrin treatment using EMD121974. RESULTS: Solid melanoma metastases were more susceptible to daily low-dose treatment of EMD121974 than multiple hematogenous metastases. Interleukin-12 had a profound effect on both types of brain metastases. After 21 days, a marked reduction of vascularity was observed in both tumor types. CONCLUSION: The combination of endogenous IL-12 production with integrin blockade resulted in additive effects for murine hematogenous brain metastases but not for focal brain metastases. Copyright
BACKGROUND: The formation of brain metastases is intrinsically linked to concomitant angiogenesis. The purpose of the present study was to investigate the combined effects of interleukin-12 (IL-12) and EMD121974 on the growth and distribution of melanoma brain metastases since both substances may interact with important steps in the cascade of brain metastases formation. MATERIALS AND METHODS:Brain metastases were induced by either stereotactic implantation of cells to the brain parenchyma or by injection of the melanoma cells into the internal carotid artery to mimic hematogenous metastatic spread in mice. Naive or IL-12-overexpressing murine K1735 melanoma cells were used either alone or in combination with intraperitoneal anti-integrin treatment using EMD121974. RESULTS: Solid melanoma metastases were more susceptible to daily low-dose treatment of EMD121974 than multiple hematogenous metastases. Interleukin-12 had a profound effect on both types of brain metastases. After 21 days, a marked reduction of vascularity was observed in both tumor types. CONCLUSION: The combination of endogenous IL-12 production with integrin blockade resulted in additive effects for murinehematogenous brain metastases but not for focal brain metastases. Copyright
Authors: Tobias Bäuerle; Dorde Komljenovic; Maximilian Merz; Martin R Berger; Simon L Goodman; Wolfhard Semmler Journal: Int J Cancer Date: 2011-05-15 Impact factor: 7.396
Authors: Tanios S Bekaii-Saab; Julie M Roda; Kristan D Guenterberg; Bhuvanaswari Ramaswamy; Donn C Young; Amy K Ferketich; Tammy A Lamb; Michael R Grever; Charles L Shapiro; William E Carson Journal: Mol Cancer Ther Date: 2009-11-03 Impact factor: 6.261
Authors: Adil I Daud; Ronald C DeConti; Stephanie Andrews; Patricia Urbas; Adam I Riker; Vernon K Sondak; Pamela N Munster; Daniel M Sullivan; Kenneth E Ugen; Jane L Messina; Richard Heller Journal: J Clin Oncol Date: 2008-11-24 Impact factor: 44.544